Deal Corner
September 01, 2009
The Merck subsidiary and Wellcome will gradually invest a sum of 45 million Pounds

DEAL BRIEF

In a first of its kind venture, a wholly owned subsidiary of US based pharmaceutical company, Merck & Co., Inc. and The Wellcome Trust, a UK based charity, involved in biomedical research and improvement of global public health, have joined hands together to form a business venture in India, albeit with a 'not-for-profit' mission. The unique combination of a pharmaceutical company and a charity coming together to form an Indian entity will specifically aim at research and development of vaccines for distribution in developing countries at affordable prices, thereby striving to improve health in low income countries. The Merck subsidiary and The Wellcome Trust will gradually invest a sum of 45 million Pounds each (approx USD 74 million each) over a period of the next seven years in the Indian JV entity, thereby acquiring a stake of 50% each in the entity.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel to Merck & Co., Inc. Our role involved advice on the kind of entity structure, assistance in setting up operations in India and documentation for the joint venture

Disclaimer

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.

Deal Corner

September 01, 2009

The Merck subsidiary and Wellcome will gradually invest a sum of 45 million Pounds

DEAL BRIEF

In a first of its kind venture, a wholly owned subsidiary of US based pharmaceutical company, Merck & Co., Inc. and The Wellcome Trust, a UK based charity, involved in biomedical research and improvement of global public health, have joined hands together to form a business venture in India, albeit with a 'not-for-profit' mission. The unique combination of a pharmaceutical company and a charity coming together to form an Indian entity will specifically aim at research and development of vaccines for distribution in developing countries at affordable prices, thereby striving to improve health in low income countries. The Merck subsidiary and The Wellcome Trust will gradually invest a sum of 45 million Pounds each (approx USD 74 million each) over a period of the next seven years in the Indian JV entity, thereby acquiring a stake of 50% each in the entity.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel to Merck & Co., Inc. Our role involved advice on the kind of entity structure, assistance in setting up operations in India and documentation for the joint venture

Disclaimer

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

NDA Connect

Connect with us at events, 
conferences and seminars.